Paricalcitol

SKU: orb1296135

Description

Paricalcitol is a selective vitamin D receptor agonist used to manage secondary hyperparathyroidism in chronic kidney disease. It is widely employed in renal research, with studies demonstrating its effects on parathyroid hormone suppression in both in vitro cell models and in vivo animal studies of renal failure.

Research Area

Metabolism Research

Key Properties

• CAS Number: 131918-61-1
• MW: 416.64
• Purity: 99.84% (May vary between batches)
• Formula: C₂₇H₄₄O₃
• SMILES: [H][C@@]12CC[C@H]([C@H](C)\C=C\[C@H](C)C(C)(C)O)[C@@]1(C)CCC\C2=C/C=C1C[C@@H](O)C[C@H](O)C1
• Target: Vitamin,Others
• Solubility: Ethanol:12 mg/mL (28.8 mM);10% DMSO+90% Corn Oil:3.3 mg/mL (7.92 mM);H2O:Insoluble;DMSO:140 mg/mL (336.02 mM)

Bioactivity

• In Vivo:
  Paricalcitol, administered at a dosage of 300 ng/kg/day, markedly reduces Tau levels and prevents left ventricular (LV) dysfunction in mice. Furthermore, this treatment significantly lowers the mRNA expression of atrial natriuretic peptide (ANP), fibronectin, and collagen III in mice subjected to transverse aortic constriction (TAC-pari) .
• In Vitro:
  Paricalcitol (30 nM; HP + PC) produces a significant reduction in calcification relative to the observed in cells in HP medium. Paricalcitol causes a reduction in the levels of nuclear β-catenin to a level similar to that observed in control cells .
• Animal Research:
  After TAC or sham surgery, a subset of the mice is treated with paricalcitol which activates the VDR, at a final dose of 300 ng/kg/day. Paricalcitol is dissolved in a 95% propylene glycol and 5% ethyl alcohol solution. Mice were intraperitoneally injected with paricalcitol (or vehicle only) three times per week on Monday, Wednesday, and Friday for five consecutive weeks. An established anti-hypertrophic and anti-fibrotic treatment, namely the angiotensin II receptor blocker (ARB) losartan is also included. Previous experiments have shown it is feasible and efficacious to dissolve losartan in the drinking water at a concentration of 30 mg/kg/day; mice are treated for five consecutive weeks. So, in total eight groups are studied. Sham (n=10), TAC (n=10), Sham + losartan (Sham-los, n=10), TAC + losartan (TAC-los, n=10), Sham + paricalcitol (Sham-pari, n=10), TAC + paricalcitol (TAC-pari, n=10), Sham + paricalcitol + losartan (Sham-combi, n=10) and TAC + paricalcitol + losartan (TAC-combi, n=10) .

Storage & Handling

• Storage: Powder: -20°C for 3 years | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Inhibitor, Paricalcitol, inhibit, VD/VDR, Vitamin D receptor, vitamin D receptor, Vitamin D

Compound Identifiers

PubChem CID

5281104